DMEMEDS shared post via Reuters: Vertex cystic fibrosis combo succeeds in key late-stage trials

(Reuters) - A combination of Vertex Pharmaceuticals Inc's cystic fibrosis drug Kalydeco and its experimental lumacaftor succeeded in improving lung function in a pair of closely watched late-stage trials of patients with the most common genetic mutation associated with the rare lung disease. [Category: healthNews] http://feeds.reuters.com/~r/reuters/healthNews/~3/ZS5MSU8ApFk/story01.htm

Read More